Tiziana Life Sciences (LON:TILS) CEO Kunwar Shailubhai speaks to Proactive London's Andrew Scott following the publication of two abstracts at the American Society of Clinical Oncology (ASCO) on the performance of its Milciclib drug in patients with advanced Hepatocellular Carcinoma. The first abstract reports Phase 2a clinical data with orally administered Milciclib in sorafenib-resistant hepatocellular carcinoma (HCC) patients, for which it met the primary endpoint. It says the oral treatment with Milciclib was well tolerated with manageable toxicities and no recorded drug-related deaths. The second abstract reports preliminary clinical data from an ongoing investigator-originated trial with a combination of orally administered Milciclib and Regorafenib in liver transplant patients with recurrent HCC.
Tiziana's Milciclib drug meets primary endpoint in Phase 2a trial in Hepatocellular Carcinoma
Quick facts: Tiziana Life Sciences PLC
Price: 110 GBX
Market Cap: £182.39 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE